印米他辛未能在健康志愿者中增加肠道透性
Michael Camilleri1, Irene Busciglio1, Paula Carlson1
1Clinical Enteric Neuroscience and Translational Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA.
Clinical and translational gastroenterology
|October 28, 2025
概括
在健康的志愿者中,印米他辛并没有持续增加肠道透性,这挑战了其作为肠道屏障研究可靠模型的使用. 需要进一步的研究来验证这种实验方法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 在实验环境中,印米他素通常用于诱导肠道的超透性.
- 该模型允许评估旨在改善肠道屏障功能的干预措施.
研究的目的:
- 评估补充剂是否可以减轻健康志愿者的印梅他辛诱导的肠道透性.
- 评估印米他辛作为诱导肠道屏障功能障碍的模型的可靠性.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的研究 (NCT05538247).
- 参与者接受了印梅他辛 (150毫克/天6天) 与安慰剂或补充剂.
- 使用13C-曼尼托和乳糖尿液分泌来测量肠道透性.
主要成果:
- 印梅他辛的使用并没有显著增加13C-曼尼托尔的分泌.
- 血清生物标志物 (素,克劳丁) 或便calprotectin.没有观察到实质性的变化.
- 预期的印美素诱导的超透性没有得到可靠的复制.
结论:
- 这些发现质疑印梅他辛在诱导健康个体的肠道超透性方面的持续有效性.
- 这项研究强调了在未来的肠道屏障研究中需要仔细考虑这个模型的可重现性和灵敏性.
- 结果表明,在临床研究中,用于评估肠道屏障干预措施的印梅他辛的使用可能存在局限性.
相关概念视频
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
493
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
493
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Drug Absorption: Factors Affecting GI Absorption
5.9K
The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
5.9K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449


